Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Researchers discover mechanism that prevents immune system from spinning out of control

A team led by a University of Arizona researcher has discovered a previously unknown mechanism that prevents the immune system from going into overdrive, shedding light not only on how our body controls its response to pathogens but on conditions such as autoimmune diseases, allergies and chronic inflammation as well.

24 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Aerobic exercise can lessen - or worsen - the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken, researchers report.

3 Jul 2013

Study reveals circadian disruption is a risk factor in alcoholic liver disease

Thirty percent of severe alcoholics develop liver disease, but scientists have not been able to explain why only a subset is at risk. A research team from Northwestern University and Rush University Medical Center now has a possible explanation: disrupted sleep and circadian rhythms can push those vulnerable over the edge to disease.

2 Jul 2013

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Soligenix, Inc. (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

1 Jul 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

The largest investigation to date has found a dramatic increase in the number of hospitalizations for children with inflammatory bowel disease during the past decade in the United States.

26 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Scientists discover protective role of retinoic acid against intestinal inflammation

Scientists at Trinity College Dublin have made novel discoveries around the protective influence of Vitamin A against the damaging immune responses that lead to inflammatory bowel disease.

5 Jun 2013

UC researchers identify biomarkers for inflammatory bowel disease

Using the Department of Defense Serum Repository, University of Cincinnati researchers have identified a number of biomarkers for inflammatory bowel disease, which could help with earlier diagnosis and intervention in those who have not yet shown symptoms.

22 May 2013

IBD patients are at higher risk of melanoma, report researchers

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in Orlando, Fla.

21 May 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Study says influenza immunization is safe in children with IBD

Influenza immunization rates in children with inflammatory bowel disease (IBD) are low despite its safety according to a new study by researchers at the Institute for Clinical Evaluative Sciences (ICES), Children's Hospital of Eastern Ontario (CHEO), the Ottawa Hospital Research Institute (OHRI), and the University of Ottawa.

7 May 2013

PET/CT may enhance detection of inflammatory bowel diseases in the future

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.

2 May 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Researchers discover mechanism that prevents immune system from spinning out of control

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Researchers report that aerobic exercise can lessen or worsen ulcerative colitis symptoms

Study reveals circadian disruption is a risk factor in alcoholic liver disease

First clinical study for development of SGX203 to treat pediatric Crohn's disease

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Reason for large increase in hospitalizations of children with IBD unclear, researchers report

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Scientists discover protective role of retinoic acid against intestinal inflammation

UC researchers identify biomarkers for inflammatory bowel disease

IBD patients are at higher risk of melanoma, report researchers

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Study says influenza immunization is safe in children with IBD

PET/CT may enhance detection of inflammatory bowel diseases in the future

Study: Biologic response modifying drugs can cause acute liver injury

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in